Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.

ABSTRACT:

Background

The outcomes of patients with stage III cutaneous melanoma who undergo complete surgical resection can be highly variable, and estimation of individual risk of disease recurrence and mortality remains imprecise. With recent demonstrations of effective adjuvant targeted and immune checkpoint inhibitor therapy, more precise stratification of patients for costly and potentially toxic adjuvant therapy is needed. We report the utility of pre-operative circulating tumour DNA (ctDNA) in patients with high-risk stage III melanoma.

Patients and methods

ctDNA was analysed in blood specimens that were collected pre-operatively from 174 patients with stage III melanoma undergoing complete lymph node (LN) dissection. Cox regression analyses were used to evaluate the prognostic

SUBMITTER: Lee JH 

PROVIDER: S-EPMC6551453 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature